Table 1.
Baseline characteristic of the included studies.
| First Author | Design | Cut-off (U/L) | Samples | Age | Male | HT (%) | DM (%) | CKD (%) | CVD (%) | CLD (%) | Outcome | NOS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Giacomelli 2020 [12] | PC | NR | 104 | NR | 30.9 | NR | NR | NR | NR | NR | Mortality | 7 |
| Guan 2020 [7] | RC | 200 | 657 | 47 | 58.1 | 15 | 7.4 | 0.7 | NR | 1.1 | Severe | 6 |
| Hong 2020 [8] | RC | NR | 98 | 55.4 | 38.8 | 30.6 | 9.2 | NR | 2 | 3.1 | ICU | 6 |
| Huang 2020 [6] | RC | 185 | 40 | 49 | 73 | 15 | 20 | NR | 15 | 2 | ICU | 6 |
| Jang 2020 [19] | RC | 145 | 110 | 56.9 | 43.6 | 33.6 | 26.4 | NR | 9.1 | 3.6 | Severe | 8 |
| Jiang 2020 [18] | RC | 185 | 59 | 64 | 49 | 42 | 15 | NR | 44 | 3 | ICU | 6 |
| Mertoglu 2020 [17] | RC | NR | 377 | 49 | 57.5 | NR | NR | NR | NR | NR | ICU | 8 |
| Wan 2020 [16] | RC | 200 | 135 | 47 | 53.3 | 9.6 | 8.9 | NR | 5.2 | NR | Severe | 6 |
| Wang 2020 [11] | RC | NR | 252 | 49 | 46.5 | 19.6 | 6.2 | 1.5 | NR | NR | Severe | 7 |
| Wei 2020 [10] | RC | 200 | 81 | 51 | 56.2 | 17 | 5.1 | NR | NR | 2.5 | Severe | 7 |
| Zhang 2020 [15] | RC | 200 | 138 | 57 | 50.7 | 30 | 12.1 | 1.4 | NR | 1.4 | Severe | 7 |
| Zhao 2020 [14] | RC | NR | 91 | 46 | 53.8 | 19.8 | 3.3 | 1.1 | NR | 1.1 | Severe | 7 |
| Zheng 2020 [9] | RC | 190 | 161 | 45 | 49.7 | 13.7 | 4.3 | NR | NR | 3.7 | Severe | 6 |
| Zhou 2020 [13] | RC | 185 | 168 | 56 | 62 | 30 | 19 | 1 | NR | 3 | Mortality | 8 |
CKD: Chronic Kidney Disease, CVD: Cardiovascular Disease, CLD: Chronic Lung Disease, HT: Hypertension, RC: Retrospective Cohort, NOS: Newcastle-Ottawa Scale, NR: Not Reported.